Cargando…
Pharmacological hypothesis: A recombinant probiotic for taming bacterial β‐glucuronidase in drug‐induced enteropathy
Advances in pharmacomicrobiomics have shed light on the pathophysiology of drug‐induced enteropathy associated with the therapeutic use of certain non‐steroidal anti‐inflammatory drugs, anticancer chemotherapies and immunosuppressants. The toxicity pathway results from the post‐glucuronidation relea...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9460963/ https://www.ncbi.nlm.nih.gov/pubmed/36082825 http://dx.doi.org/10.1002/prp2.998 |
_version_ | 1784786870878601216 |
---|---|
author | Jardou, Manon Brossier, Clarisse Guiyedi, Kenza Faucher, Quentin Lawson, Roland |
author_facet | Jardou, Manon Brossier, Clarisse Guiyedi, Kenza Faucher, Quentin Lawson, Roland |
author_sort | Jardou, Manon |
collection | PubMed |
description | Advances in pharmacomicrobiomics have shed light on the pathophysiology of drug‐induced enteropathy associated with the therapeutic use of certain non‐steroidal anti‐inflammatory drugs, anticancer chemotherapies and immunosuppressants. The toxicity pathway results from the post‐glucuronidation release and digestive accumulation of an aglycone generated in the context of intestinal dysbiosis characterized by the expansion of β‐glucuronidase‐expressing bacteria. The active aglycone could trigger direct or indirect inflammatory signaling on the gut epithelium. Therefore, taming bacterial β‐glucuronidase (GUS) activity is a druggable target for preventing drug‐induced enteropathy. In face of the limitations of antibiotic strategies that can worsen intestinal dysbiosis and impair immune functions, we hereby propose the use of a recombinant probiotic capable of mimicking repressive conditions of GUS through an inducible plasmid vector. |
format | Online Article Text |
id | pubmed-9460963 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94609632022-09-28 Pharmacological hypothesis: A recombinant probiotic for taming bacterial β‐glucuronidase in drug‐induced enteropathy Jardou, Manon Brossier, Clarisse Guiyedi, Kenza Faucher, Quentin Lawson, Roland Pharmacol Res Perspect Original Articles Advances in pharmacomicrobiomics have shed light on the pathophysiology of drug‐induced enteropathy associated with the therapeutic use of certain non‐steroidal anti‐inflammatory drugs, anticancer chemotherapies and immunosuppressants. The toxicity pathway results from the post‐glucuronidation release and digestive accumulation of an aglycone generated in the context of intestinal dysbiosis characterized by the expansion of β‐glucuronidase‐expressing bacteria. The active aglycone could trigger direct or indirect inflammatory signaling on the gut epithelium. Therefore, taming bacterial β‐glucuronidase (GUS) activity is a druggable target for preventing drug‐induced enteropathy. In face of the limitations of antibiotic strategies that can worsen intestinal dysbiosis and impair immune functions, we hereby propose the use of a recombinant probiotic capable of mimicking repressive conditions of GUS through an inducible plasmid vector. John Wiley and Sons Inc. 2022-09-09 /pmc/articles/PMC9460963/ /pubmed/36082825 http://dx.doi.org/10.1002/prp2.998 Text en © 2022 The Authors. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Jardou, Manon Brossier, Clarisse Guiyedi, Kenza Faucher, Quentin Lawson, Roland Pharmacological hypothesis: A recombinant probiotic for taming bacterial β‐glucuronidase in drug‐induced enteropathy |
title | Pharmacological hypothesis: A recombinant probiotic for taming bacterial β‐glucuronidase in drug‐induced enteropathy |
title_full | Pharmacological hypothesis: A recombinant probiotic for taming bacterial β‐glucuronidase in drug‐induced enteropathy |
title_fullStr | Pharmacological hypothesis: A recombinant probiotic for taming bacterial β‐glucuronidase in drug‐induced enteropathy |
title_full_unstemmed | Pharmacological hypothesis: A recombinant probiotic for taming bacterial β‐glucuronidase in drug‐induced enteropathy |
title_short | Pharmacological hypothesis: A recombinant probiotic for taming bacterial β‐glucuronidase in drug‐induced enteropathy |
title_sort | pharmacological hypothesis: a recombinant probiotic for taming bacterial β‐glucuronidase in drug‐induced enteropathy |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9460963/ https://www.ncbi.nlm.nih.gov/pubmed/36082825 http://dx.doi.org/10.1002/prp2.998 |
work_keys_str_mv | AT jardoumanon pharmacologicalhypothesisarecombinantprobioticfortamingbacterialbglucuronidaseindruginducedenteropathy AT brossierclarisse pharmacologicalhypothesisarecombinantprobioticfortamingbacterialbglucuronidaseindruginducedenteropathy AT guiyedikenza pharmacologicalhypothesisarecombinantprobioticfortamingbacterialbglucuronidaseindruginducedenteropathy AT faucherquentin pharmacologicalhypothesisarecombinantprobioticfortamingbacterialbglucuronidaseindruginducedenteropathy AT lawsonroland pharmacologicalhypothesisarecombinantprobioticfortamingbacterialbglucuronidaseindruginducedenteropathy |